Copyright Reports & Markets. All rights reserved.

Global H2 Blockers Market Research Report 2021

Request for Sample of this report
Buy now

1 H2 Blockers Market Overview

  • 1.1 Product Overview and Scope of H2 Blockers
  • 1.2 H2 Blockers Segment by Type
    • 1.2.1 Global H2 Blockers Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Ranitidine/Zantac
    • 1.2.3 Cimetidine
    • 1.2.4 Famotidine
    • 1.2.5 Nazatidine
  • 1.3 H2 Blockers Segment by Application
    • 1.3.1 H2 Blockers Sales Comparison by Application: (2021-2027)
    • 1.3.2 Retail Stores
    • 1.3.3 Clinics
    • 1.3.4 Hospitals
    • 1.3.5 OTC Sales
  • 1.4 Global H2 Blockers Market Size Estimates and Forecasts
    • 1.4.1 Global H2 Blockers Revenue 2016-2027
    • 1.4.2 Global H2 Blockers Sales 2016-2027
    • 1.4.3 H2 Blockers Market Size by Region: 2016 Versus 2021 Versus 2027

2 H2 Blockers Market Competition by Manufacturers

  • 2.1 Global H2 Blockers Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global H2 Blockers Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global H2 Blockers Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers H2 Blockers Manufacturing Sites, Area Served, Product Type
  • 2.5 H2 Blockers Market Competitive Situation and Trends
    • 2.5.1 H2 Blockers Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest H2 Blockers Players Market Share by Revenue
    • 2.5.3 Global H2 Blockers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 H2 Blockers Retrospective Market Scenario by Region

  • 3.1 Global H2 Blockers Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global H2 Blockers Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America H2 Blockers Market Facts & Figures by Country
    • 3.3.1 North America H2 Blockers Sales by Country
    • 3.3.2 North America H2 Blockers Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe H2 Blockers Market Facts & Figures by Country
    • 3.4.1 Europe H2 Blockers Sales by Country
    • 3.4.2 Europe H2 Blockers Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific H2 Blockers Market Facts & Figures by Region
    • 3.5.1 Asia Pacific H2 Blockers Sales by Region
    • 3.5.2 Asia Pacific H2 Blockers Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America H2 Blockers Market Facts & Figures by Country
    • 3.6.1 Latin America H2 Blockers Sales by Country
    • 3.6.2 Latin America H2 Blockers Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa H2 Blockers Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa H2 Blockers Sales by Country
    • 3.7.2 Middle East and Africa H2 Blockers Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global H2 Blockers Historic Market Analysis by Type

  • 4.1 Global H2 Blockers Sales Market Share by Type (2016-2021)
  • 4.2 Global H2 Blockers Revenue Market Share by Type (2016-2021)
  • 4.3 Global H2 Blockers Price by Type (2016-2021)

5 Global H2 Blockers Historic Market Analysis by Application

  • 5.1 Global H2 Blockers Sales Market Share by Application (2016-2021)
  • 5.2 Global H2 Blockers Revenue Market Share by Application (2016-2021)
  • 5.3 Global H2 Blockers Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Acic Pharmaceuticals
    • 6.1.1 Acic Pharmaceuticals Corporation Information
    • 6.1.2 Acic Pharmaceuticals Description and Business Overview
    • 6.1.3 Acic Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Acic Pharmaceuticals Product Portfolio
    • 6.1.5 Acic Pharmaceuticals Recent Developments/Updates
  • 6.2 Actavis Mid Atlantic LLC
    • 6.2.1 Actavis Mid Atlantic LLC Corporation Information
    • 6.2.2 Actavis Mid Atlantic LLC Description and Business Overview
    • 6.2.3 Actavis Mid Atlantic LLC H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Actavis Mid Atlantic LLC Product Portfolio
    • 6.2.5 Actavis Mid Atlantic LLC Recent Developments/Updates
  • 6.3 Ajanta Pharma
    • 6.3.1 Ajanta Pharma Corporation Information
    • 6.3.2 Ajanta Pharma Description and Business Overview
    • 6.3.3 Ajanta Pharma H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Ajanta Pharma Product Portfolio
    • 6.3.5 Ajanta Pharma Recent Developments/Updates
  • 6.4 AmerisourceBergen
    • 6.4.1 AmerisourceBergen Corporation Information
    • 6.4.2 AmerisourceBergen Description and Business Overview
    • 6.4.3 AmerisourceBergen H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 AmerisourceBergen Product Portfolio
    • 6.4.5 AmerisourceBergen Recent Developments/Updates
  • 6.5 Amneal Pharmaceuticals
    • 6.5.1 Amneal Pharmaceuticals Corporation Information
    • 6.5.2 Amneal Pharmaceuticals Description and Business Overview
    • 6.5.3 Amneal Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Amneal Pharmaceuticals Product Portfolio
    • 6.5.5 Amneal Pharmaceuticals Recent Developments/Updates
  • 6.6 ANDA Repository
    • 6.6.1 ANDA Repository Corporation Information
    • 6.6.2 ANDA Repository Description and Business Overview
    • 6.6.3 ANDA Repository H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 ANDA Repository Product Portfolio
    • 6.6.5 ANDA Repository Recent Developments/Updates
  • 6.7 Ani Pharmaceuticals
    • 6.6.1 Ani Pharmaceuticals Corporation Information
    • 6.6.2 Ani Pharmaceuticals Description and Business Overview
    • 6.6.3 Ani Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Ani Pharmaceuticals Product Portfolio
    • 6.7.5 Ani Pharmaceuticals Recent Developments/Updates
  • 6.8 Apotex Inc. (and Apotex Corporation)
    • 6.8.1 Apotex Inc. (and Apotex Corporation) Corporation Information
    • 6.8.2 Apotex Inc. (and Apotex Corporation) Description and Business Overview
    • 6.8.3 Apotex Inc. (and Apotex Corporation) H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Apotex Inc. (and Apotex Corporation) Product Portfolio
    • 6.8.5 Apotex Inc. (and Apotex Corporation) Recent Developments/Updates
  • 6.9 Appco Pharma
    • 6.9.1 Appco Pharma Corporation Information
    • 6.9.2 Appco Pharma Description and Business Overview
    • 6.9.3 Appco Pharma H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Appco Pharma Product Portfolio
    • 6.9.5 Appco Pharma Recent Developments/Updates
  • 6.10 Aurobindo Pharma
    • 6.10.1 Aurobindo Pharma Corporation Information
    • 6.10.2 Aurobindo Pharma Description and Business Overview
    • 6.10.3 Aurobindo Pharma H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Aurobindo Pharma Product Portfolio
    • 6.10.5 Aurobindo Pharma Recent Developments/Updates
  • 6.11 Ben Venue Laboratories Inc.
    • 6.11.1 Ben Venue Laboratories Inc. Corporation Information
    • 6.11.2 Ben Venue Laboratories Inc. H2 Blockers Description and Business Overview
    • 6.11.3 Ben Venue Laboratories Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Ben Venue Laboratories Inc. Product Portfolio
    • 6.11.5 Ben Venue Laboratories Inc. Recent Developments/Updates
  • 6.12 Boehringer Ingelheim
    • 6.12.1 Boehringer Ingelheim Corporation Information
    • 6.12.2 Boehringer Ingelheim H2 Blockers Description and Business Overview
    • 6.12.3 Boehringer Ingelheim H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Boehringer Ingelheim Product Portfolio
    • 6.12.5 Boehringer Ingelheim Recent Developments/Updates
  • 6.13 Breckenridge Pharmaceuticals
    • 6.13.1 Breckenridge Pharmaceuticals Corporation Information
    • 6.13.2 Breckenridge Pharmaceuticals H2 Blockers Description and Business Overview
    • 6.13.3 Breckenridge Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 Breckenridge Pharmaceuticals Product Portfolio
    • 6.13.5 Breckenridge Pharmaceuticals Recent Developments/Updates
  • 6.14 Contract Pharmacal Corp.
    • 6.14.1 Contract Pharmacal Corp. Corporation Information
    • 6.14.2 Contract Pharmacal Corp. H2 Blockers Description and Business Overview
    • 6.14.3 Contract Pharmacal Corp. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 Contract Pharmacal Corp. Product Portfolio
    • 6.14.5 Contract Pharmacal Corp. Recent Developments/Updates
  • 6.15 Dr. Reddy's Laboratories Inc.
    • 6.15.1 Dr. Reddy's Laboratories Inc. Corporation Information
    • 6.15.2 Dr. Reddy's Laboratories Inc. H2 Blockers Description and Business Overview
    • 6.15.3 Dr. Reddy's Laboratories Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.15.4 Dr. Reddy's Laboratories Inc. Product Portfolio
    • 6.15.5 Dr. Reddy's Laboratories Inc. Recent Developments/Updates
  • 6.16 Geri-Care Pharmaceuticals
    • 6.16.1 Geri-Care Pharmaceuticals Corporation Information
    • 6.16.2 Geri-Care Pharmaceuticals H2 Blockers Description and Business Overview
    • 6.16.3 Geri-Care Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.16.4 Geri-Care Pharmaceuticals Product Portfolio
    • 6.16.5 Geri-Care Pharmaceuticals Recent Developments/Updates
  • 6.17 GlaxoSmithKline
    • 6.17.1 GlaxoSmithKline Corporation Information
    • 6.17.2 GlaxoSmithKline H2 Blockers Description and Business Overview
    • 6.17.3 GlaxoSmithKline H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.17.4 GlaxoSmithKline Product Portfolio
    • 6.17.5 GlaxoSmithKline Recent Developments/Updates
  • 6.18 Glenmark Pharmaceuticals
    • 6.18.1 Glenmark Pharmaceuticals Corporation Information
    • 6.18.2 Glenmark Pharmaceuticals H2 Blockers Description and Business Overview
    • 6.18.3 Glenmark Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.18.4 Glenmark Pharmaceuticals Product Portfolio
    • 6.18.5 Glenmark Pharmaceuticals Recent Developments/Updates
  • 6.19 Granules Pharmaceuticals Inc.
    • 6.19.1 Granules Pharmaceuticals Inc. Corporation Information
    • 6.19.2 Granules Pharmaceuticals Inc. H2 Blockers Description and Business Overview
    • 6.19.3 Granules Pharmaceuticals Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.19.4 Granules Pharmaceuticals Inc. Product Portfolio
    • 6.19.5 Granules Pharmaceuticals Inc. Recent Developments/Updates
  • 6.20 Heritage Pharma Labs Inc.
    • 6.20.1 Heritage Pharma Labs Inc. Corporation Information
    • 6.20.2 Heritage Pharma Labs Inc. H2 Blockers Description and Business Overview
    • 6.20.3 Heritage Pharma Labs Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.20.4 Heritage Pharma Labs Inc. Product Portfolio
    • 6.20.5 Heritage Pharma Labs Inc. Recent Developments/Updates
  • 6.21 Hikma Pharmaceuticals
    • 6.21.1 Hikma Pharmaceuticals Corporation Information
    • 6.21.2 Hikma Pharmaceuticals H2 Blockers Description and Business Overview
    • 6.21.3 Hikma Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.21.4 Hikma Pharmaceuticals Product Portfolio
    • 6.21.5 Hikma Pharmaceuticals Recent Developments/Updates
  • 6.22 Hi-Tech Pharmacal Co.
    • 6.22.1 Hi-Tech Pharmacal Co. Corporation Information
    • 6.22.2 Hi-Tech Pharmacal Co. H2 Blockers Description and Business Overview
    • 6.22.3 Hi-Tech Pharmacal Co. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.22.4 Hi-Tech Pharmacal Co. Product Portfolio
    • 6.22.5 Hi-Tech Pharmacal Co. Recent Developments/Updates
  • 6.23 Lannett Co.
    • 6.23.1 Lannett Co. Corporation Information
    • 6.23.2 Lannett Co. H2 Blockers Description and Business Overview
    • 6.23.3 Lannett Co. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.23.4 Lannett Co. Product Portfolio
    • 6.23.5 Lannett Co. Recent Developments/Updates
  • 6.24 Mylan Pharmaceuticals Inc.
    • 6.24.1 Mylan Pharmaceuticals Inc. Corporation Information
    • 6.24.2 Mylan Pharmaceuticals Inc. H2 Blockers Description and Business Overview
    • 6.24.3 Mylan Pharmaceuticals Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.24.4 Mylan Pharmaceuticals Inc. Product Portfolio
    • 6.24.5 Mylan Pharmaceuticals Inc. Recent Developments/Updates
  • 6.25 Nostrum Laboratories Inc.
    • 6.25.1 Nostrum Laboratories Inc. Corporation Information
    • 6.25.2 Nostrum Laboratories Inc. H2 Blockers Description and Business Overview
    • 6.25.3 Nostrum Laboratories Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.25.4 Nostrum Laboratories Inc. Product Portfolio
    • 6.25.5 Nostrum Laboratories Inc. Recent Developments/Updates
  • 6.26 Novitium Pharma
    • 6.26.1 Novitium Pharma Corporation Information
    • 6.26.2 Novitium Pharma H2 Blockers Description and Business Overview
    • 6.26.3 Novitium Pharma H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.26.4 Novitium Pharma Product Portfolio
    • 6.26.5 Novitium Pharma Recent Developments/Updates
  • 6.27 PAI Holdings, LLC
    • 6.27.1 PAI Holdings, LLC Corporation Information
    • 6.27.2 PAI Holdings, LLC H2 Blockers Description and Business Overview
    • 6.27.3 PAI Holdings, LLC H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.27.4 PAI Holdings, LLC Product Portfolio
    • 6.27.5 PAI Holdings, LLC Recent Developments/Updates
  • 6.28 Par Pharmaceutical Inc.
    • 6.28.1 Par Pharmaceutical Inc. Corporation Information
    • 6.28.2 Par Pharmaceutical Inc. H2 Blockers Description and Business Overview
    • 6.28.3 Par Pharmaceutical Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.28.4 Par Pharmaceutical Inc. Product Portfolio
    • 6.28.5 Par Pharmaceutical Inc. Recent Developments/Updates
  • 6.29 Perrigo
    • 6.29.1 Perrigo Corporation Information
    • 6.29.2 Perrigo H2 Blockers Description and Business Overview
    • 6.29.3 Perrigo H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.29.4 Perrigo Product Portfolio
    • 6.29.5 Perrigo Recent Developments/Updates
  • 6.30 Ranbaxy Inc.
    • 6.30.1 Ranbaxy Inc. Corporation Information
    • 6.30.2 Ranbaxy Inc. H2 Blockers Description and Business Overview
    • 6.30.3 Ranbaxy Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.30.4 Ranbaxy Inc. Product Portfolio
    • 6.30.5 Ranbaxy Inc. Recent Developments/Updates
  • 6.31 Sandoz Inc.
    • 6.31.1 Sandoz Inc. Corporation Information
    • 6.31.2 Sandoz Inc. H2 Blockers Description and Business Overview
    • 6.31.3 Sandoz Inc. H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.31.4 Sandoz Inc. Product Portfolio
    • 6.31.5 Sandoz Inc. Recent Developments/Updates
  • 6.32 Sanofi-Aventis
    • 6.32.1 Sanofi-Aventis Corporation Information
    • 6.32.2 Sanofi-Aventis H2 Blockers Description and Business Overview
    • 6.32.3 Sanofi-Aventis H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.32.4 Sanofi-Aventis Product Portfolio
    • 6.32.5 Sanofi-Aventis Recent Developments/Updates
  • 6.33 Strides
    • 6.33.1 Strides Corporation Information
    • 6.33.2 Strides H2 Blockers Description and Business Overview
    • 6.33.3 Strides H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.33.4 Strides Product Portfolio
    • 6.33.5 Strides Recent Developments/Updates
  • 6.34 Sun Pharma
    • 6.34.1 Sun Pharma Corporation Information
    • 6.34.2 Sun Pharma H2 Blockers Description and Business Overview
    • 6.34.3 Sun Pharma H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.34.4 Sun Pharma Product Portfolio
    • 6.34.5 Sun Pharma Recent Developments/Updates
  • 6.35 Taro Pharmaceuticals
    • 6.35.1 Taro Pharmaceuticals Corporation Information
    • 6.35.2 Taro Pharmaceuticals H2 Blockers Description and Business Overview
    • 6.35.3 Taro Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.35.4 Taro Pharmaceuticals Product Portfolio
    • 6.35.5 Taro Pharmaceuticals Recent Developments/Updates
  • 6.36 Teva Pharmaceuticals
    • 6.36.1 Teva Pharmaceuticals Corporation Information
    • 6.36.2 Teva Pharmaceuticals H2 Blockers Description and Business Overview
    • 6.36.3 Teva Pharmaceuticals H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.36.4 Teva Pharmaceuticals Product Portfolio
    • 6.36.5 Teva Pharmaceuticals Recent Developments/Updates
  • 6.37 Thirty Madison
    • 6.37.1 Thirty Madison Corporation Information
    • 6.37.2 Thirty Madison H2 Blockers Description and Business Overview
    • 6.37.3 Thirty Madison H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.37.4 Thirty Madison Product Portfolio
    • 6.37.5 Thirty Madison Recent Developments/Updates
  • 6.38 Torrent Pharma
    • 6.38.1 Torrent Pharma Corporation Information
    • 6.38.2 Torrent Pharma H2 Blockers Description and Business Overview
    • 6.38.3 Torrent Pharma H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.38.4 Torrent Pharma Product Portfolio
    • 6.38.5 Torrent Pharma Recent Developments/Updates
  • 6.39 Unique Pharmaceutical Laboratories
    • 6.39.1 Unique Pharmaceutical Laboratories Corporation Information
    • 6.39.2 Unique Pharmaceutical Laboratories H2 Blockers Description and Business Overview
    • 6.39.3 Unique Pharmaceutical Laboratories H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.39.4 Unique Pharmaceutical Laboratories Product Portfolio
    • 6.39.5 Unique Pharmaceutical Laboratories Recent Developments/Updates
  • 6.40 VKT Pharma
    • 6.40.1 VKT Pharma Corporation Information
    • 6.40.2 VKT Pharma H2 Blockers Description and Business Overview
    • 6.40.3 VKT Pharma H2 Blockers Sales, Revenue and Gross Margin (2016-2021)
    • 6.40.4 VKT Pharma Product Portfolio
    • 6.40.5 VKT Pharma Recent Developments/Updates

7 H2 Blockers Manufacturing Cost Analysis

  • 7.1 H2 Blockers Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of H2 Blockers
  • 7.4 H2 Blockers Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 H2 Blockers Distributors List
  • 8.3 H2 Blockers Customers

9 H2 Blockers Market Dynamics

  • 9.1 H2 Blockers Industry Trends
  • 9.2 H2 Blockers Growth Drivers
  • 9.3 H2 Blockers Market Challenges
  • 9.4 H2 Blockers Market Restraints

10 Global Market Forecast

  • 10.1 H2 Blockers Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of H2 Blockers by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of H2 Blockers by Type (2022-2027)
  • 10.2 H2 Blockers Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of H2 Blockers by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of H2 Blockers by Application (2022-2027)
  • 10.3 H2 Blockers Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of H2 Blockers by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of H2 Blockers by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Ranitidine/Zantac
    Cimetidine
    Famotidine
    Nazatidine

    Segment by Application
    Retail Stores
    Clinics
    Hospitals
    OTC Sales

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Acic Pharmaceuticals
    Actavis Mid Atlantic LLC
    Ajanta Pharma
    AmerisourceBergen
    Amneal Pharmaceuticals
    ANDA Repository
    Ani Pharmaceuticals
    Apotex Inc. (and Apotex Corporation)
    Appco Pharma
    Aurobindo Pharma
    Ben Venue Laboratories Inc.
    Boehringer Ingelheim
    Breckenridge Pharmaceuticals
    Contract Pharmacal Corp.
    Dr. Reddy's Laboratories Inc.
    Geri-Care Pharmaceuticals
    GlaxoSmithKline
    Glenmark Pharmaceuticals
    Granules Pharmaceuticals Inc.
    Heritage Pharma Labs Inc.
    Hikma Pharmaceuticals
    Hi-Tech Pharmacal Co.
    Lannett Co.
    Mylan Pharmaceuticals Inc.
    Nostrum Laboratories Inc.
    Novitium Pharma
    PAI Holdings, LLC
    Par Pharmaceutical Inc.
    Perrigo
    Ranbaxy Inc.
    Sandoz Inc.
    Sanofi-Aventis
    Strides
    Sun Pharma
    Taro Pharmaceuticals
    Teva Pharmaceuticals
    Thirty Madison
    Torrent Pharma
    Unique Pharmaceutical Laboratories
    VKT Pharma

    Buy now